Cancer Combo Collaborations Held Back By IP, Complexity – PSA Panelists
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite strides in recent years toward more cross-company collaborations to test cancer drugs in combination, most deals remain short-term, early-stage clinical partnerships, according to panelists at the Pharmaceutical Strategy Conference.